What's new — Masld¶
Generated 2026-11-01 from the publication dates of every paper cited in this condition's pages.
This page answers a different question from the curation log. The log says when we last edited a page; this says how recent the evidence on those pages is — so you can tell settled ground from a field that is actively moving, and jump straight to what has emerged lately.
How much of this condition's evidence is recent¶
| Published within | Cited papers |
|---|---|
| last week | 3 |
| last month | 6 |
| last 2 months | 11 |
| last 3 months | 13 |
| last 6 months | 18 |
| last year | 48 |
| older than a year | 325 |
Counts are cumulative: a paper from last week also counts inside "last month". Dates are PubMed publication or e-publication dates, so a paper may have appeared online before its journal issue.
Newest evidence first¶
The most recent cited papers, with the pages that use them.
| Published | Paper | Cited on |
|---|---|---|
| 2026-11-01 | Taiwan GEST-TASL-TMASO Joint Position Statement in Managing Metabolic Dysfunction-Associated Steatotic Liver Disease and Obesity — Liver Int ([PMID 42922180](https://pubmed.ncbi.nlm.nih.gov/42922180/){target="_blank" rel="noopener"}) | guidelines |
| 2026-11-01 | The aMAP Score Effectively Stratifies Hepatocellular Carcinoma Risk in the Steatotic Liver Disease Population — Liver Int ([PMID 42904608](https://pubmed.ncbi.nlm.nih.gov/42904608/){target="_blank" rel="noopener"}) | masld-related-hepatocellular-carcinoma |
| 2026-11-01 | Understanding MASLD and diabetes through lived experience — Diabetologia ([PMID 42525136](https://pubmed.ncbi.nlm.nih.gov/42525136/){target="_blank" rel="noopener"}) | patient-experience-and-advocacy |
| 2026-10-02 | The Madrid Declaration on metabolic dysfunction-associated steatotic liver disease (MASLD). Innovation, equity, and transformation of the health-system response to the metabolic disease challenge of the 21st century — Rev Esp Enferm Dig ([PMID 42929259](https://pubmed.ncbi.nlm.nih.gov/42929259/){target="_blank" rel="noopener"}) | guidelines |
| 2026-10-02 | Patients with MASH experience worse health-related quality of life: a multinational real-world study using LiverMultiScan — Qual Life Res ([PMID 42911297](https://pubmed.ncbi.nlm.nih.gov/42911297/){target="_blank" rel="noopener"}) | patient-experience-and-advocacy |
| 2026-10-02 | Genome-wide analyses identify 60 loci associated with liver triglyceride content — Nat Genet ([PMID 42907524](https://pubmed.ncbi.nlm.nih.gov/42907524/){target="_blank" rel="noopener"}) | genetics |
| 2026-10-01 | Gaps in awareness of metabolic liver disease among high-risk populations in the United States — Hepatol Commun ([PMID 42900157](https://pubmed.ncbi.nlm.nih.gov/42900157/){target="_blank" rel="noopener"}) | patient-experience-and-advocacy |
| 2026-10-01 | Phase 2 study of fazpilodemab, a FGFR1/Klothoβ agonist, in metabolic dysfunction-associated steatohepatitis (MASH) — JHEP Rep ([PMID 42892346](https://pubmed.ncbi.nlm.nih.gov/42892346/){target="_blank" rel="noopener"}) | other-pharmacotherapy |
| 2026-10-01 | Thyroid hormone receptor-β agonist simedeutirom (HSK31679) for Chinese patients with metabolic dysfunction-associated steatohepatitis: a 52-week, multicentre, randomised, double-blind, placebo-controlled, phase 2b trial — Lancet Gastroenterol Hepatol ([PMID 42887516](https://pubmed.ncbi.nlm.nih.gov/42887516/){target="_blank" rel="noopener"}) | clinical-trials-landscape, resmetirom-and-thyromimetics |
| 2026-10-01 | Characteristics and outcomes of lean versus non-lean metabolic dysfunction-associated steatohepatitis liver transplant recipients — Ann Hepatol ([PMID 42869334](https://pubmed.ncbi.nlm.nih.gov/42869334/){target="_blank" rel="noopener"}) | lean-masld |
| 2026-09-02 | EASL-EASD-EASO guidance on the use of resmetirom and semaglutide as MASH-targeted therapy — J Hepatol ([PMID 42805503](https://pubmed.ncbi.nlm.nih.gov/42805503/){target="_blank" rel="noopener"}) | guidelines |
| 2026-08-07 | Sequential FIB-4-based testing limits detection of fibrotic MASLD despite optimized ELF thresholds — Hepatol Commun ([PMID 42566274](https://pubmed.ncbi.nlm.nih.gov/42566274/){target="_blank" rel="noopener"}) | noninvasive-assessment, red-flags-and-safety-concerns |
| 2026-08-02 | Baveno VIII - Advancing consensus in portal hypertension — J Hepatol ([PMID 42624290](https://pubmed.ncbi.nlm.nih.gov/42624290/){target="_blank" rel="noopener"}) | guidelines |
| 2026-08-01 | Lived Experience, Concerns, and Support Needs of Adults with Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): A Qualitative Study — Healthcare (Basel) ([PMID 42651339](https://pubmed.ncbi.nlm.nih.gov/42651339/){target="_blank" rel="noopener"}) | patient-experience-and-advocacy |
| 2026-08-01 | Efficacy of Luseogliflozin Added to Semaglutide in Patients With Metabolic Dysfunction-Associated Steatohepatitis and Type 2 Diabetes Mellitus: A Randomised, Open-Label Trial — Diabetes Obes Metab ([PMID 42605535](https://pubmed.ncbi.nlm.nih.gov/42605535/){target="_blank" rel="noopener"}) | masld-and-type-2-diabetes |
| 2026-07-01 | A qualitative study on the self-management experience and needs of postmenopausal patients with metabolic dysfunction-associated steatotic liver disease from the perspective of active health — Front Public Health ([PMID 42529177](https://pubmed.ncbi.nlm.nih.gov/42529177/){target="_blank" rel="noopener"}) | patient-experience-and-advocacy |
| 2026-07-01 | Recompensation of decompensated cirrhosis in a spectrum of metabolic dysfunction-related steatotic liver disease, with PEth-corroborated alcohol abstinence and modification of cardiometabolic risk factors — Hepatology ([PMID 42467948](https://pubmed.ncbi.nlm.nih.gov/42467948/){target="_blank" rel="noopener"}) | cirrhosis-and-decompensation |
| 2026-06-01 | Sleeve gastrectomy versus Roux-en-Y gastric bypass for nonalcoholic fatty liver disease: a systematic review and meta-analysis — Surg Obes Relat Dis ([PMID 42420150](https://pubmed.ncbi.nlm.nih.gov/42420150/){target="_blank" rel="noopener"}) | bariatric-and-metabolic-surgery |
| 2026-05-01 | Subtype Differences in Major Adverse Liver Outcomes and Cardiovascular Events and Mortality in Steatotic Liver Disease: A UK Biobank Analysis — Aliment Pharmacol Ther ([PMID 42120953](https://pubmed.ncbi.nlm.nih.gov/42120953/){target="_blank" rel="noopener"}) | natural-history-and-fibrosis-progression |
| 2026-05-01 | Evidence-based clinical practice guidelines for metabolic dysfunction-associated steatotic liver disease (MASLD) 2026 — J Gastroenterol ([PMID 42120590](https://pubmed.ncbi.nlm.nih.gov/42120590/){target="_blank" rel="noopener"}) | guidelines |
| 2026-04-07 | Updated Global Consensus Recommendations for Risk Stratification, Treatment Initiation, and Response Monitoring in Metabolic Dysfunction-Associated Steatotic Liver Disease — Clin Gastroenterol Hepatol ([PMID 41950980](https://pubmed.ncbi.nlm.nih.gov/41950980/){target="_blank" rel="noopener"}) | clinical-trials-landscape, guidelines, red-flags-and-safety-concerns |
| 2026-04-01 | Differential Impact of Metabolic Bariatric Surgery Versus Semaglutide on Adverse Hepatic and Extrahepatic Outcomes in Individuals With Metabolic Dysfunction-Associated Steatotic Liver Disease and Type 2 Diabetes — Diabetes Obes Metab ([PMID 41969188](https://pubmed.ncbi.nlm.nih.gov/41969188/){target="_blank" rel="noopener"}) | bariatric-and-metabolic-surgery, glp1-and-incretin-therapy |
| 2026-04-01 | Increased Cardiovascular and Cerebrovascular Events in Patients With Lean vs Non-lean MASLD: A Multicenter Analysis — Clin Transl Gastroenterol ([PMID 41614694](https://pubmed.ncbi.nlm.nih.gov/41614694/){target="_blank" rel="noopener"}) | lean-masld |
| 2026-03-06 | Long-term prognosis of lean MASLD: evidence from three population-based prospective cohorts — Gut ([PMID 41093635](https://pubmed.ncbi.nlm.nih.gov/41093635/){target="_blank" rel="noopener"}) | lean-masld |
| 2026-03-02 | Quantitative regression of qFibrosis with resmetirom: Exploratory histologic endpoints from the MAESTRO-NASH phase III clinical trial — J Hepatol ([PMID 41895606](https://pubmed.ncbi.nlm.nih.gov/41895606/){target="_blank" rel="noopener"}) | resmetirom-and-thyromimetics |
| 2026-03-02 | AISF practice guidance on pharmacological treatment of metabolic-dysfunction associated steatotic liver disease and steatohepatitis (MASLD/MASH): A 2026 Update — Dig Liver Dis ([PMID 41864758](https://pubmed.ncbi.nlm.nih.gov/41864758/){target="_blank" rel="noopener"}) | guidelines |
| 2026-03-01 | From Policy to Practice: Knowledge gaps and training outcomes related to MASLD guidelines among medical officers in Chhattisgarh, India — BMC Health Serv Res ([PMID 41845319](https://pubmed.ncbi.nlm.nih.gov/41845319/){target="_blank" rel="noopener"}) | guidelines |
| 2026-02-04 | MASLD, MASH, and the CKM Spectrum: A Roadmap for Multiorgan Clinical Trial Design — J Am Coll Cardiol ([PMID 41636667](https://pubmed.ncbi.nlm.nih.gov/41636667/){target="_blank" rel="noopener"}) | cardiovascular-and-extrahepatic-outcomes |
| 2026-02-03 | Rising burden of MASLD and CKM syndrome in Asia: A decade of trends and future projections — Metabolism ([PMID 41643809](https://pubmed.ncbi.nlm.nih.gov/41643809/){target="_blank" rel="noopener"}) | cardiovascular-and-extrahepatic-outcomes, epidemiology-and-burden |
| 2026-02-02 | Comparative efficacy of pharmacologic therapies for MASLD in improving fibrosis: systematic review and network meta-analysis — Eur J Gastroenterol Hepatol ([PMID 41811770](https://pubmed.ncbi.nlm.nih.gov/41811770/){target="_blank" rel="noopener"}) | resmetirom-and-thyromimetics |
| 2026-02-02 | HFpEF and MASLD: converging mechanisms and clinical implications — Nat Rev Cardiol ([PMID 41735546](https://pubmed.ncbi.nlm.nih.gov/41735546/){target="_blank" rel="noopener"}) | cardiovascular-and-extrahepatic-outcomes |
| 2026-02-01 | Underuse of statins in MASLD despite population-based associations with lower liver stiffness — JHEP Rep ([PMID 41861677](https://pubmed.ncbi.nlm.nih.gov/41861677/){target="_blank" rel="noopener"}) | red-flags-and-safety-concerns |
| 2026-02-01 | Epidemiology, screening, and co-management of type 2 diabetes mellitus and metabolic dysfunction-associated steatotic liver disease — Hepatology ([PMID 38722246](https://pubmed.ncbi.nlm.nih.gov/38722246/){target="_blank" rel="noopener"}) | masld-and-type-2-diabetes |
| 2026-01-13 | Metabolic Dysfunction-Associated Steatotic Liver Disease in Adults: A Review — JAMA ([PMID 41212550](https://pubmed.ncbi.nlm.nih.gov/41212550/){target="_blank" rel="noopener"}) | epidemiology-and-burden, masld-and-type-2-diabetes, nomenclature-and-definitions, overview, red-flags-and-safety-concerns |
| 2026-01-09 | The Impact of Body Weight Change on Liver Histology in Metabolic Dysfunction-Associated Steatotic Liver Disease Across Various Histological Endpoints: A Systematic Review and Meta-Analysis — Am J Gastroenterol ([PMID 41510965](https://pubmed.ncbi.nlm.nih.gov/41510965/){target="_blank" rel="noopener"}) | lifestyle-and-weight-loss |
| 2026-01-01 | Evaluation of Stigma Toward Fatty Liver Disease — Endocr Metab Immune Disord Drug Targets ([PMID 40337974](https://pubmed.ncbi.nlm.nih.gov/40337974/){target="_blank" rel="noopener"}) | patient-experience-and-advocacy |
| 2025-12-01 | Incretin-Based Therapies and Post-Bariatric Surgery Alcohol Use Disorder — JAMA Netw Open ([PMID 41632137](https://pubmed.ncbi.nlm.nih.gov/41632137/){target="_blank" rel="noopener"}) | bariatric-and-metabolic-surgery |
| 2025-12-01 | Cardiovascular-kidney-metabolic syndrome and the risk of liver fibrosis progression and liver-related events in MASLD — Hepatology ([PMID 41400631](https://pubmed.ncbi.nlm.nih.gov/41400631/){target="_blank" rel="noopener"}) | cardiovascular-and-extrahepatic-outcomes |
| 2025-12-01 | GLP-1RA and Liver Fibrosis Progression in MASLD and Type 2 Diabetes: Target Trial Emulation Using Propensity Score Matching — Liver Int ([PMID 41250965](https://pubmed.ncbi.nlm.nih.gov/41250965/){target="_blank" rel="noopener"}) | glp1-and-incretin-therapy |
| 2025-11-07 | Semaglutide therapy for metabolic dysfunction-associated steatohepatitis: November 2025 updates to AASLD Practice Guidance — Hepatology ([PMID 41201884](https://pubmed.ncbi.nlm.nih.gov/41201884/){target="_blank" rel="noopener"}) | glp1-and-incretin-therapy, guidelines, overview, red-flags-and-safety-concerns |
| 2025-11-04 | Long-Term Glycemic Control and the Risk of Liver Stiffness Progression and Liver-Related Events in MASLD — Clin Gastroenterol Hepatol ([PMID 41076043](https://pubmed.ncbi.nlm.nih.gov/41076043/){target="_blank" rel="noopener"}) | masld-and-type-2-diabetes |
| 2025-11-03 | Cost-Effectiveness of MASH Diagnosis and Management Approaches Among Those With Type 2 Diabetes — JAMA Netw Open ([PMID 41196592](https://pubmed.ncbi.nlm.nih.gov/41196592/){target="_blank" rel="noopener"}) | masld-and-type-2-diabetes, noninvasive-assessment |
| 2025-11-02 | Association Between Subclinical Hypothyroidism and MASLD: A Systematic Review and Meta-Analysis — Int J Hepatol ([PMID 41357781](https://pubmed.ncbi.nlm.nih.gov/41357781/){target="_blank" rel="noopener"}) | resmetirom-and-thyromimetics |
| 2025-11-02 | Metabolic dysfunction-associated steatotic liver disease and adverse pregnancy outcomes: a nationwide cohort study — Hepatol Int ([PMID 41307877](https://pubmed.ncbi.nlm.nih.gov/41307877/){target="_blank" rel="noopener"}) | red-flags-and-safety-concerns |
| 2025-11-02 | Aspirin and hepatocellular carcinoma risk in metabolic dysfunction-associated steatotic liver disease: nationwide cohort study with genetic risk analysis — Clin Mol Hepatol ([PMID 41287437](https://pubmed.ncbi.nlm.nih.gov/41287437/){target="_blank" rel="noopener"}) | masld-related-hepatocellular-carcinoma |
| 2025-11-02 | Cardiovascular-kidney-metabolic (CKM) syndrome is associated with increased mortality in individuals with metabolic dysfunction-associated steatotic liver disease (MASLD) — Commun Med (Lond) ([PMID 41272273](https://pubmed.ncbi.nlm.nih.gov/41272273/){target="_blank" rel="noopener"}) | cardiovascular-and-extrahepatic-outcomes |
| 2025-11-01 | Predictors of fibrosis, clinical events, and mortality in MASLD: Data from the Global-MASLD study — Hepatology ([PMID 41231627](https://pubmed.ncbi.nlm.nih.gov/41231627/){target="_blank" rel="noopener"}) | masld-and-type-2-diabetes, natural-history-and-fibrosis-progression |
| 2025-11-01 | The ANTICIPATE-NASH Models Stratify Better the Risk of Clinical Events Than Histology in Metabolic Dysfunction-Associated Steatotic Liver Disease Patients With Advanced Chronic Liver Disease — Gastroenterology ([PMID 41212130](https://pubmed.ncbi.nlm.nih.gov/41212130/){target="_blank" rel="noopener"}) | cirrhosis-and-decompensation, clinical-trials-landscape, guidelines, overview |
Trials — what has moved¶
67 registered trials are cited by this condition's pages. Registry records were re-checked live when this page was generated, so status, enrolment and results-posting below reflect ClinicalTrials.gov as of that date.
| Registry activity | Trials |
|---|---|
| trial records updated in the last week | 3 |
| trial records updated in the last month | 11 |
| trial records updated in the last 2 months | 16 |
| trial records updated in the last 3 months | 17 |
| trial records updated in the last 6 months | 28 |
| trial records updated in the last year | 36 |
Recently updated registrations¶
Posted efficacy and safety results¶
Trials whose sponsors have posted results to the registry. Adverse-event figures are participant counts summed across all arms as reported — read them against enrolment, and follow the registry link for the arm-by-arm breakdown that determines whether a signal is real.
| Results posted | Trial | Phase | N | Primary outcome | Serious AE | Other AE | Deaths |
|---|---|---|---|---|---|---|---|
| 2026-10-28 | A Study to Evaluate AZD2693 in Participants Who Are Carriers of the PN | PHASE2 | 220 | Proportion of Participants Achieving NASH Resolution Without Worsening | 17 | 151 | 0 |
| 2026-07-21 | A Study of Efruxifermin in Subjects With Compensated Cirrhosis Due to | PHASE2 | 213 | Main: Change From Baseline in Fibrosis With no Worsening Steatohepatit | 43 | 203 | 1 |
| 2026-01-06 | Study Evaluating the Safety, Efficacy and Tolerability of BIO89-100 in | PHASE2 | 222 | Main Study: Number of Participants With Histological Resolution of Non | 22 | 186 | 0 |
| 2025-12-23 | Phase 2 Study of MGL-3196 in Patients With Non-Alcoholic Steatohepatit | PHASE2 | 125 | Percent Change From Baseline To Week 12 In Hepatic Fat Fraction Assess | 7 | 107 | 0 |
| 2025-05-09 | Study of TVB-2640 in Subjects With Nonalcoholic Steatohepatitis (NASH) | PHASE2 | 168 | Histological Improvement in Nonalcoholic Fatty Liver Disease (NAFLD) A | 16 | 115 | 0 |
| 2025-05-08 | A Study of Efruxifermin in Non-Cirrhotic Subjects With Histologically | PHASE2 | 128 | Effect of Efruxifermin (EFX) vs Placebo on Fibrosis Regression in Part | 15 | 123 | 0 |
| 2025-01-24 | A Study of Tirzepatide (LY3298176) in Participants With Nonalcoholic S | PHASE2 | 190 | Percentage of Participants With Absence of Nonalcoholic Steatohepatiti | 12 | 170 | 0 |
| 2024-12-03 | A Study to Test Safety and Efficacy of Survodutide (BI456906) in Adult | PHASE2 | 295 | Improvement (Yes/ no) From Baseline in Liver Histological Findings Bas | 22 | 262 | 0 |
| 2024-09-19 | Lanifibranor in Patients With Type 2 Diabetes & Nonalcoholic Fatty Liv | PHASE2 | 128 | Change in Intrahepatic Triglycerides (IHTG) Quantified by Proton Magne | 1 | 38 | 0 |
| 2024-09-05 | Randomized Global Phase 3 Study to Evaluate the Impact on NASH With Fi | PHASE3 | 2477 | Time to the First Adjudicated Event for Clinical Outcome Composite End | 797 | 2392 | 47 |
| 2024-05-29 | A Research Study on How Semaglutide Works in People With Fatty Liver D | PHASE2 | 71 | Percentage of Participants With At Least One Stage of Liver Fibrosis I | 8 | 53 | 0 |
| 2024-04-16 | A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of BFKB | PHASE2 | 46 | Proportion of Participants With NASH Resolution on Overall Histopathol | 2 | 39 | 0 |
| 2023-11-15 | A Study of Efinopegdutide (MK-6024) in Participants With Nonalcoholic | PHASE2 | 145 | Mean Relative Reduction From Baseline in Liver Fat Content (LFC) Measu | 2 | 101 | 0 |
| 2023-09-13 | A Study of LY3437943 in Participants Who Have Obesity or Are Overweigh | PHASE2 | 338 | Mean Percent Change From Baseline in Body Weight | 13 | 241 | 1 |
| 2022-03-23 | Phase 3 Study to Evaluate the Efficacy and Safety of Elafibranor Versu | PHASE3 | 2157 | Number of Elafibranor-treated Participants Relative to Placebo Achievi | 285 | 1828 | 9 |
30 of these trials are still recruiting or active — see the condition's clinical trials page for the full landscape.
Which pages rest on the newest evidence¶
🔥 marks a page citing three or more papers from the last year — the pages worth re-reading if you have been away.
| Page | Newest citation | In last year | Total citations |
|---|---|---|---|
| guidelines | 2026-11-01 | 10 | 43 |
| masld-related-hepatocellular-carcinoma | 2026-11-01 | 2 | 21 |
| patient-experience-and-advocacy | 2026-11-01 | 6 | 22 |
| genetics | 2026-10-02 | 1 | 21 |
| clinical-trials-landscape | 2026-10-01 | 3 | 30 |
| lean-masld | 2026-10-01 | 3 | 16 |
| other-pharmacotherapy | 2026-10-01 | 1 | 24 |
| resmetirom-and-thyromimetics | 2026-10-01 | 4 | 20 |
| noninvasive-assessment | 2026-08-07 | 2 | 25 |
| red-flags-and-safety-concerns | 2026-08-07 | 6 | 50 |
| masld-and-type-2-diabetes | 2026-08-01 | 6 | 26 |
| cirrhosis-and-decompensation | 2026-07-01 | 2 | 22 |
| bariatric-and-metabolic-surgery | 2026-06-01 | 3 | 14 |
| natural-history-and-fibrosis-progression | 2026-05-01 | 2 | 22 |
| glp1-and-incretin-therapy | 2026-04-01 | 3 | 21 |
| cardiovascular-and-extrahepatic-outcomes | 2026-02-04 | 5 | 32 |
| epidemiology-and-burden | 2026-02-03 | 2 | 30 |
| nomenclature-and-definitions | 2026-01-13 | 1 | 27 |
| overview | 2026-01-13 | 3 | 45 |
| lifestyle-and-weight-loss | 2026-01-09 | 1 | 15 |
| pathogenesis | 2025-09-01 | 0 | 26 |
| histology-and-biopsy | 2025-04-02 | 0 | 18 |
Recency is not quality: an old paper may be the definitive one, and a new paper may not replicate. Use this to find movement, not to rank evidence. See open questions for what remains unresolved, and the curation log for when these pages were last revised.